Form D · Biotechnology
NanoString Technologies Inc
Seattle, WA · CIK 0001401708
Offering snapshot reported May 13, 2013 · SEC filing
- Reported sold
- $150K Offering amount: $150K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 30, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 13, 2013 | Initial | $150,000 | No comparison | 2 | SEC filing |
| Jan 10, 2013 | Initial | $0 | No comparison | 2 | SEC filing |
| Dec 21, 2012 | Initial | $274,999 | No comparison | 2 | SEC filing |
| Dec 12, 2012 | Initial | $15,317,413 | No comparison | 15 | SEC filing |
| Apr 12, 2012 | Initial | $0 | No comparison | 2 | SEC filing |
| Nov 14, 2011 | Initial | $19,999,998 | No comparison | 10 | SEC filing |
| Jun 29, 2011 | Initial | $2,500,000 | No comparison | 5 | SEC filing |
| Nov 22, 2010 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 25, 2010 | Initial | $0 | No comparison | 1 | SEC filing |
| Jun 22, 2009 | Initial | $14,000,000 | No comparison | 6 | SEC filing |
| Oct 1, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 25, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 24, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-196355
Source: Form D, filed May 13, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mary Tedd Allen | Executive |
| Joseph Beechem | Executive |
| Wayne Burns | Executive |
| J. Wayne Cowens | Executive |
| John Wayne Cowens | Executive |
| Perry Fell | Director |
| H. Perry Fell | Director |
| Jennifer Scott Fonstad | Director |
| Nicholas Galakatos | Director |
| Nicholas Galaktos | Director |
| Robert Bradley Gray | Director, Executive |
| James Johnson | Executive |
| Finny Kuruvilla | Director |
| Nalini Murdter | Executive |
| Gregory Norden | Director |
| Gary Riordan | Executive |
| Barney Saunders | Executive |
| Bruce Seeley | Executive |
| Kathryn Surace Smith | Executive |
| Charles Waite | Director |
| Williams D Young | Director |
| William D. Young | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
530 Fairview Avenue North Suite 2000
Seattle, WA, 98109
Seattle, WA, 98109